Risks and benefits of infliximab for the treatment of Crohn's disease - Test2 - elhamkhani - TriplyDB

Risks and benefits of infliximab for the treatment of Crohn's disease

Risks and benefits of infliximab for the treatment of Crohn's disease

http://www.wikidata.org/entity/Q28252207

about

Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data The diagnosis and treatment of Crohn's disease and ulcerative colitis Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Predicting response to Anti-TNF Agents for the treatment of crohn's disease.Infliximab: the evidence for its place in therapy in ulcerative colitis.Nv-52: a novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease.Cancer and immunomodulators in inflammatory bowel diseases.An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease.Risks and benefits of biologic therapy for inflammatory bowel diseases.Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease.Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006.Inflammatory bowel disease: past, present, and future The role of TNFalpha in ulcerative colitis.Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?Recent advances in the medical therapy of Crohn's disease in childhood.Infliximab therapy for pediatric Crohn's disease.Treatment of inflammatory bowel disease: a review of medical therapy.Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach Top-down therapy for Crohn's disease: rationale and evidence.Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease.Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review.Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy.Inflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel.Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future.International variation in medication prescription rates among elderly patients with inflammatory bowel disease.Emerging drugs to treat Crohn's disease.Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab.Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.Give me prednisone and give me death.Crohn’s disease: Advise and consent.

P2860

Q26823547-5D19F7FA-A156-4DBE-8715-C05ED5BC9528 Q26862821-124FB84F-207B-44D9-9650-F0E99ABAC59D Q26864906-8E9A547C-C6F7-4722-A6E5-4CCF5AC840CB Q33476811-37BC3907-E0D3-492B-B2E5-C6DDDA6EA647 Q33756924-77613C67-DF5C-4C75-914D-9B9A9FE886F5 Q34078707-1D90E88D-3A15-4E7C-A662-B3C75A28177F Q34408990-7A49FE12-E80D-4976-A752-1A1A633736E7 Q34449876-AEBF7397-F1D2-4CBB-93FB-A80D3D5DBE42 Q34654654-FF75ECD9-5173-4756-A1D9-1E534E531CC9 Q35534959-AFECF5C2-3E78-45BF-BE5A-6F026BAF2159 Q35586236-D351B72E-59F8-4123-A2D8-7A22D71DE520 Q35929544-245C5689-79E6-4CC5-99E6-B1FDB7594D90 Q36167373-6A9A64BE-3F23-4236-84D5-92A1A300C5DC Q36390363-00DB408A-ADE5-40BC-B9CD-76341BD42180 Q36739682-0D39EAEE-A084-45B0-A78E-E472005CB84B Q36745440-76BD779B-55EC-4520-A799-28564C7DF0C1 Q36849148-C3DF3E24-262C-48E9-A050-5CD838950391 Q36864836-FEDF4507-0A0A-486C-8AB3-60516B706CBD Q36968175-65AF51C0-E981-4208-8665-CEB31542E81D Q37012073-2A2F6DBC-CEFA-4F49-A8DD-89F7070B45BB Q37058862-00E2F44D-8C46-486B-AD08-6150543BDD5B Q37156633-3EAE13C9-906A-4B8A-AE59-ADEB3F3FD150 Q37681484-A6D525CE-C44C-4DE9-888C-37D953266B4E Q37682521-9B49B92A-0931-4787-BC73-E04A40B5C9CC Q37789693-3BD1FEE8-7E66-4A81-B701-D3ABD71F65E1 Q37814549-854D8D0B-EEF8-4AA7-A57A-780DBB33632A Q37820898-5AF863E1-2904-4FD9-B0E6-9F09E108A1B1 Q38055211-49448DC9-5DC9-4BE4-BB0E-98F0D8847E65 Q38108468-4FCAB2D6-95F0-447B-B699-A8550EDD7FCB Q38302725-F0135275-E10E-4A51-8819-98AA9B77AC80 Q38323592-3427799C-040A-4FA7-B5E4-748EF6457B65 Q38810502-E1AA35A6-F5B8-4046-B3DA-FBAADFD05653 Q39252060-5D70616A-C7E5-496D-815E-2DF1AB6091DB Q39546198-A6AEE59F-DAAA-40CE-BE29-673386E968DC Q39881787-1AA8DDD4-EF47-4B0D-A890-79BBF4EB9594 Q41857036-A66B630F-39F1-4384-A02F-B5DB87BCC0E4 Q43450427-F89737EB-D55C-4F33-AEBF-89C52B106B6D Q45862308-345BC31D-5E7A-421F-8D7C-08EE0BC02A0C Q46189963-16663DA7-D806-4D17-A5FC-2F8C40FD4058 Q46484666-2B6CF110-2BF5-46D3-9D4D-FF37CD0FF517

P2860

Risks and benefits of infliximab for the treatment of Crohn's disease

http://www.wikidata.org/entity/Q28252207

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Risks and benefits of infliximab for the treatment of Crohn's disease

@ast

Risks and benefits of infliximab for the treatment of Crohn's disease

@en

Risks and benefits of infliximab for the treatment of Crohn's disease

@nl

type

label

Risks and benefits of infliximab for the treatment of Crohn's disease

@ast

Risks and benefits of infliximab for the treatment of Crohn's disease

@en

Risks and benefits of infliximab for the treatment of Crohn's disease

@nl

prefLabel

Risks and benefits of infliximab for the treatment of Crohn's disease

@ast

Risks and benefits of infliximab for the treatment of Crohn's disease

@en

Risks and benefits of infliximab for the treatment of Crohn's disease

@nl

P1433

Q28252207-7A30E25F-017D-45A2-8126-4D661EF33E70

P1476

Q28252207-1A41BD71-BF0D-4966-AF89-5B899CD7B4C1

P2093

Q28252207-1480D50B-08FA-442F-ABAC-8356B4D49F53

Q28252207-9B2259F7-D122-4EE9-93D0-556897FE8DF1

Q28252207-F30C18CF-E288-450F-8480-A36499A619EC

Q28252207-F50931B8-4DE5-4B2F-9A99-95A698ABFA99

P304

Q28252207-2FFB0606-E9C4-4275-AFE0-FBC4E6E85EF6

P31

Q28252207-8e93f80f-7895-4f27-9994-330c55b8cac5

Q28252207-A20147A7-F1C6-457E-B72C-08E04F0CECAB

P356

Q28252207-CD5767E7-8BE8-4FA4-BE64-8F9E43509429

P407

Q28252207-C14CE95C-AC69-445A-BD8D-444484EF69C7

P433

Q28252207-D1C01397-99E6-449C-B907-6D7E70C75047

P478

Q28252207-7D180D05-DDE4-439F-BD46-5661CA770850

P50

Q28252207-D65FD258-212D-49A4-A02D-9B097F187E8E

P577

Q28252207-81638A0E-8BDB-42A3-B783-24B9ED29381C

P698

Q28252207-2A19274C-3405-4870-BC2B-E10DF8E496E7

P921

Q28252207-7CC46472-19F9-41D1-8855-95BF6715B5B2

P356

J.CGH.2006.05.020

P1433

Clinical Gastroenterology and Hepatology

P1476

Risks and benefits of infliximab for the treatment of Crohn's disease

@en

P2093

Bruce E Sands

http://www.w3.org/2001/XMLSchema#string

Corey A Siegel

http://www.w3.org/2001/XMLSchema#string

G Scott Gazelle

http://www.w3.org/2001/XMLSchema#string

Joshua R Korzenik

http://www.w3.org/2001/XMLSchema#string

P304

1017-24; quiz 976

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2006.05.020

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16843733

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease